Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Motility

Efficacy of oral ghrelin agonist in diabetic gastroparesis

The oral ghrelin agonist TZP-102 was tested in a phase IIb randomized trial in 201 patients with diabetic gastroparesis. TZP-102 administered at 10 mg or 20 mg daily for 12 weeks had no substantial effect on diabetic gastroparesis symptoms as determined using the Daily Diary of Gastroparesis Symptoms Questionnaire, when compared with patients given placebo. However, a marked symptom improvement was observed in all patients over the trial period.

ORIGINAL RESEARCH PAPER

  1. 1

    McCallum, R. W. et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol. Motil. doi:10.1111/nmo.12184

Download references

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Efficacy of oral ghrelin agonist in diabetic gastroparesis. Nat Rev Gastroenterol Hepatol 10, 502 (2013). https://doi.org/10.1038/nrgastro.2013.157

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing